Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on US Physical Therapy (USPH – Research Report) and CareDx (CDNA – Research Report).
US Physical Therapy (USPH)
Barrington analyst Michael Petusky maintained a Buy rating on US Physical Therapy today and set a price target of $111.00. The company’s shares closed last Thursday at $82.61, close to its 52-week low of $78.08.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of
Currently, the analyst consensus on US Physical Therapy is a Strong Buy with an average price target of $112.25, implying a 36.6% upside from current levels. In a report issued on November 3, Bank of America Securities also maintained a Buy rating on the stock with a $110.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
CareDx (CDNA)
H.C. Wainwright analyst Yi Chen reiterated a Hold rating on CareDx today. The company’s shares closed last Thursday at $7.70.
According to TipRanks.com, Chen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CareDx with a $12.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on USPH:
- U.S. Physical Therapy reports Q3 adjusted EPS 62c, consensus 61c
- USPH Earnings this Week: How Will it Perform?
- U.S. Physical Therapy acquires an injury prevention, ergonomics business for $4M
- U.S. Physical Therapy acquires two physical therapy practices for $13.9M
- U.S. Physical Therapy initiated with an Overweight at JPMorgan
